Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology

Baldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., Christmas, D. M., Davies, S., Fineberg, N., Lidbetter, N., Malizia, A., McCrone, P., Nabarro, D., O'Neill, C., Scott, J., van der Wee, N. & Wittchen, H-U., May-2014, In : Journal of Psychopharmacology. 28, 5, p. 403-439 37 p.

Research output: Contribution to journalReview articleAcademicpeer-review

  • David S. Baldwin
  • Ian M. Anderson
  • David J. Nutt
  • Christer Allgulander
  • Borwin Bandelow
  • Johan A. den Boer
  • David M. Christmas
  • Simon Davies
  • Naomi Fineberg
  • Nicky Lidbetter
  • Andrea Malizia
  • Paul McCrone
  • Daniel Nabarro
  • Catherine O'Neill
  • Jan Scott
  • Nic van der Wee
  • Hans-Ulrich Wittchen

This revision of the 2005 British Association for Psychopharmacology guidelines for the evidence-based pharmacological treatment of anxiety disorders provides an update on key steps in diagnosis and clinical management, including recognition, acute treatment, longer-term treatment, combination treatment, and further approaches for patients who have not responded to first-line interventions. A consensus meeting involving international experts in anxiety disorders reviewed the main subject areas and considered the strength of supporting evidence and its clinical implications. The guidelines are based on available evidence, were constructed after extensive feedback from participants, and are presented as recommendations to aid clinical decision-making in primary, secondary and tertiary medical care. They may also serve as a source of information for patients, their carers, and medicines management and formulary committees.

Original languageEnglish
Pages (from-to)403-439
Number of pages37
JournalJournal of Psychopharmacology
Issue number5
Publication statusPublished - May-2014


  • pregabalin, anxiety disorders, benzodiazepines, post-traumatic stress disorder, social anxiety disorder, anxiolytics, separation anxiety disorder, Anticonvulsants, generalised anxiety disorder, antidepressants, evidence-based guidelines, antipsychotics, cognitive behaviour therapy, serotonin-noradrenaline reuptake inhibitor, panic disorder, selective serotonin reuptake inhibitor, specific phobia, treatment, obsessive-compulsive disorder, RANDOMIZED CONTROLLED-TRIAL, COGNITIVE-BEHAVIORAL THERAPY, PLACEBO-CONTROLLED TRIAL, VENLAFAXINE EXTENDED-RELEASE, PRIMARY-CARE PATIENTS, EVIDENCE-BASED PHARMACOTHERAPY, SEROTONIN REUPTAKE INHIBITORS, QUALITY-OF-LIFE, MAJOR DEPRESSIVE DISORDER, RESISTANT PANIC DISORDER

ID: 15992219